Robert J Huang1, Nirav C Thosani1, Monique T Barakat1, Abhishek Choudhary1, Alka Mithal2, Gurkirpal Singh3, Saurabh Sethi1, Subhas Banerjee1. 1. Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California, USA. 2. Institute of Clinical Outcomes Research and Education (ICORE), Woodside, California, USA. 3. Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California, USA; Institute of Clinical Outcomes Research and Education (ICORE), Woodside, California, USA.
Abstract
BACKGROUND AND AIMS: Bile duct surgery (BDS), percutaneous transhepatic cholangiography (PTC), and ERCP are alternative interventions used to treat biliary disease. Our aim was to describe trends in ERCP, BDS, and PTC on a nationwide level in the United States. METHODS: We used the National Inpatient Sample to estimate age-standardized utilization trends of inpatient diagnostic ERCP, therapeutic ERCP, BDS, and PTC between 1998 and 2013. We calculated average case fatality, length of stay, patient demographic profile (age, gender, payer), and hospital characteristics (hospital size and metropolitan status) for these procedures. RESULTS: Total biliary interventions decreased over the study period from 119.8 to 100.1 per 100,000. Diagnostic ERCP utilization decreased by 76%, and therapeutic ERCP utilization increased by 35%. BDS rates decreased by 78% and PTC rates by 24%. ERCP has almost completely supplanted surgery for the management of choledocholithiasis. Fatality from ERCP, BDS, and PTC have all decreased, whereas mean length of stay has remained stable. The proportion of Medicare-insured, Medicaid-insured, and uninsured patients undergoing biliary procedures has increased over time. Most of the increase in therapeutic ERCP and decrease in BDS occurred in large, metropolitan hospitals. CONCLUSIONS: Although therapeutic ERCP utilization has increased over time, the total volume of biliary interventions has decreased. BDS utilization has experienced the most dramatic decrease, possibly a consequence of the increased therapeutic capacity and safety of ERCP. ERCPs are now predominantly therapeutic in nature. Large urban hospitals are leading the shift from surgical to endoscopic therapy of the biliary system.
BACKGROUND AND AIMS: Bile duct surgery (BDS), percutaneous transhepatic cholangiography (PTC), and ERCP are alternative interventions used to treat biliary disease. Our aim was to describe trends in ERCP, BDS, and PTC on a nationwide level in the United States. METHODS: We used the National Inpatient Sample to estimate age-standardized utilization trends of inpatient diagnostic ERCP, therapeutic ERCP, BDS, and PTC between 1998 and 2013. We calculated average case fatality, length of stay, patient demographic profile (age, gender, payer), and hospital characteristics (hospital size and metropolitan status) for these procedures. RESULTS: Total biliary interventions decreased over the study period from 119.8 to 100.1 per 100,000. Diagnostic ERCP utilization decreased by 76%, and therapeutic ERCP utilization increased by 35%. BDS rates decreased by 78% and PTC rates by 24%. ERCP has almost completely supplanted surgery for the management of choledocholithiasis. Fatality from ERCP, BDS, and PTC have all decreased, whereas mean length of stay has remained stable. The proportion of Medicare-insured, Medicaid-insured, and uninsured patients undergoing biliary procedures has increased over time. Most of the increase in therapeutic ERCP and decrease in BDS occurred in large, metropolitan hospitals. CONCLUSIONS: Although therapeutic ERCP utilization has increased over time, the total volume of biliary interventions has decreased. BDS utilization has experienced the most dramatic decrease, possibly a consequence of the increased therapeutic capacity and safety of ERCP. ERCPs are now predominantly therapeutic in nature. Large urban hospitals are leading the shift from surgical to endoscopic therapy of the biliary system.
Authors: John T Maple; Tamir Ben-Menachem; Michelle A Anderson; Vasundhara Appalaneni; Subhas Banerjee; Brooks D Cash; Laurel Fisher; M Edwyn Harrison; Robert D Fanelli; Norio Fukami; Steven O Ikenberry; Rajeev Jain; Khalid Khan; Mary Lee Krinsky; Laura Strohmeyer; Jason A Dominitz Journal: Gastrointest Endosc Date: 2010-01 Impact factor: 9.427
Authors: J M Scheiman; R C Carlos; J L Barnett; G H Elta; T T Nostrant; W D Chey; I R Francis; P S Nandi Journal: Am J Gastroenterol Date: 2001-10 Impact factor: 10.864
Authors: Christopher Decker; John D Christein; Milind A Phadnis; C Mel Wilcox; Shyam Varadarajulu Journal: Surg Endosc Date: 2011-03-04 Impact factor: 4.584
Authors: Anne F Peery; Seth D Crockett; Caitlin C Murphy; Jennifer L Lund; Evan S Dellon; J Lucas Williams; Elizabeth T Jensen; Nicholas J Shaheen; Alfred S Barritt; Sarah R Lieber; Bharati Kochar; Edward L Barnes; Y Claire Fan; Virginia Pate; Joseph Galanko; Todd H Baron; Robert S Sandler Journal: Gastroenterology Date: 2018-10-10 Impact factor: 22.682
Authors: Zachary M Sellers; Donna MacIsaac; Helen Yu; Melody Dehghan; Ke-You Zhang; Rachel Bensen; Jessie J Wong; Cindy Kin; K T Park Journal: Gastroenterology Date: 2018-04-13 Impact factor: 22.682